Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab

W. J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Because metastatic breast cancer (MBC) is incurable in most cases, the goals of treatment are improvement in quality of life, management of symptoms, and prolonged survival. The human epidermal growth factor receptor 2 (HER2) is overexpressed in up to 30% of breast tumors, and before the development of HER-targeted therapy, HER2 positivity was predictive of poorer clinical outcomes. Trastuzumab and pertuzumab (anti-HER2 monoclonal antibodies), lapatinib (a small molecule inhibitor of HER2 and the epidermal growth factor receptor [EGFR]) are approved for treating HER2-positive MBC in the United States. Although trastuzumab plus chemotherapy is currently regarded as the first-line standard of care for HER2-positive MBC, it is not without shortcomings; these include its association with certain adverse events (e.g. cardiotoxic effect) and development of resistance. A number of investigational agents that target HER2 and other members of that receptor family are in clinical development for patients with HER2-positive MBC whose disease has progressed on trastuzumab. In addition, in an effort to overcome treatment resistance, clinical trials are evaluating combination therapy (investigational HER-targeted agents with trastuzumab or lapatinib). This review discusses recently completed and ongoing phase II and III clinical trials of investigational HER-targeted agents in the setting of trastuzumabprogressive, HER2-positive MBC.

Original languageEnglish (US)
Pages (from-to)2492-2500
Number of pages9
JournalAnnals of Oncology
Issue number10
StatePublished - Oct 2013


  • Her inhibitors
  • Her2-positive
  • Metastatic breast cancer
  • Monoclonal antibodies
  • Neoadjuvant therapy
  • Trastuzumab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab'. Together they form a unique fingerprint.

Cite this